Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 431-439

  Kurowski, V ^a   Wagner, T ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Fractionated ifosfamide therapy; Urinary ifosfamide metabolites; Urinary mesna excretion

Indexed keywords

ACROLEIN; CHLOROACETALDEHYDE; DRUG METABOLITE; IFOSFAMIDE; MESNA; THIOL DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MESNA; MIDDLE AGED;

EID: 0031040943     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050594     Document Type: Article

References (42)

1. Alarcon RA (1968) Fluorometric determination of acrolein and related compounds with m-aminophenol. Anal Chem 40:1704 1708
2. Allen LM, Creaven PJ, Nelson RL (1976) Studies on the human pharmacokinetics of isophosphoramide. Cancer Treat Rep 60:451 458
3. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuons infusion in children. Cancer Res 53:3758 3764
4. Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR (1995) Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 31 A:69 76
5. Boos J, Welslau U, Ritter J, Blaschke G, Sehellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28:445 460
6. Brade WP, Herdrich K, Varini M (1985) Ifosfamide pharmacolocy, safety and therapeutic potential. Cancer Treat Rev 12:1 47
7. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittel forschung 29:659-661
8. Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377-1387
9. Bryant BM, Jarman M, Ford HT, Smith IE (1980) Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulfonate sodium (mesna) in patients with advanced carcinoma. Lancet 11:657-659
10. Burk CD, Restinao I, Kaplan BS, Meadows AT (1990) Ifosfamide induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 117:331-335
11. Burkert H, Lucker PW, Wetzelsberger N, Bruel HP (1984) Bioavailability of orally administered mesna. Arzneimitte/forschung 34:1597-1600
12. Cox PJ (1979) Cyclophosphamide cystitis. Identification of acrolein as the causative agent. Biochem Pharmacol 28:2045 2049
13. Draeger U, Peter G, Hohorst HJ (1976) Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 60:355-359
14. Drings P, Abel U, Bülzebruck H, Stiefel P, Kleckow M, Manke HG (1986) Experience with ifosfamide combinations (etoposide or DDP) in non-small-cell lung cancer. Cancer Chemother Pharmacol 18 [Suppl 2]:34-39
15. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
16. Gilard V, Malet-Martino MC, De Forni M, Niemeyer U, Ader JC, Martino R (1993) Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Cancer Chemother Pharmacol 31:388-394
17. Goren MP (1991) Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography. J Chromatogr Biomed Appl 570:351-355
18. Goren MP, Pratt CB, Viar MJ (1989) Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 25:70-72
19. Goren MP, Pratt CB, Meyer WH, Wright RK, Dodge RK, Viar MG (1989) Mesna excretion and ifosfamide nephrotoxicity in children. Cancer Res 49:7153-7157
20. Hill DL, Laster WR Jr, Kirk MC, El Dareer S, Struck RF (1973) Metabolism of iphosphamide and production of a toxic iphosphamide metabolite. Cancer Res 33:1016-1022
21. Ikeuchi I, Amano T (1985) Fluorometric determination of 4-hydroxyifosfamide in blood and urine. Chem Pharm Bull (Tokyo) 33:2416-2420
22. Ikeuchi I, Amano T (1985) Simultaneous determination of 2-mercaptoethansulfonate and its disulfide in human urine by isotachophoresis. Chem Pharm Bull (Tokyo) 33:3016-3019
23. James CA, Mant TGK, Rogers HJ (1987) Pharmacokinetics of intravenous and oral sodium 2-mercaptoethanesulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23:561-565
24. Klein HO, Wickramanayake PD, Christian E, Coerper C (1984) Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, ASTA Z 7557). Cancer 54:1193-1203
25. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42
26. Kurowski V, Cerny T, Küpfer A, Wagner T (1991) Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 118 [Suppl IV]:S148 S153
27. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30: 725-732
28. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49:753-757
29. Lind MJ, McGown AT, Hadfield JA, Thatcher N, Crowther D, Fox BW (1989) The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38:1835-1840
30. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111
31. 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260:1133-1144
32. Morgan LR, Harrison EF, Hawke JE, Hunter HL, Constanzi JJ, Plotkin D, Tucker WG, Worall PM (1982) Toxicity of single- vs fractionated-dose ifosfamide in non small cell lung cancer: a multicenter study. Semin Oncol [Suppl 1]: 66-70
33. Norpoth K (1976) Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 60:437 443
34. Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N (1983) Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulphonate in the rat. Cancer Res 43:333 338
35. Roth B, Cerny T, Brunner KW, Küpfer A (1989) Bioverfügbarkeit von Natrium-2-mercaptoethansulfonat im Urin nach intravenöser, subkutaner und kontinuierlich subkutaner Applikation. Schweiz Med Wochenschr 119:1153-1158
36. Scheef W, Klein HO, Brock N, Burket H, Günther U, Hoefer-Janker H, Mitrenga D, Schnittser J, Voigtmann R (1979) Controlled clinical studies with an antidote against the urotoxicity of oxaza-phosphorines: preliminary results. Cancer Treat Rep 63:501-505
37. Shaw IC, Weeks MS (1987) Excretion of disodium bis-2-mercaptoethane sulphonate in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 23:933-935
38. Skinner R, Sharkey IM, Pearson ADJ, Craft AW (1993) Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173-190
39. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301-355
40. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439-456
41. Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ (1981) Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100:95-104
42. Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schröder M, Heim M (1987) Cisplatin etoposide versus ifosfamide etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J Clin Oncol 5:1880-1889